Sintx Technologies, Inc. 8-K

What Happened

• SINTX Technologies, Inc. (SINT) filed an 8-K reporting an executive leadership change. Eric Olson will stop serving as President effective March 16, 2026, and will continue as Chairman of the Board and Chief Executive Officer. On February 17, 2026 the company announced that Ryan Elmore has been appointed President, effective March 16, 2026; Mr. Elmore will report to the Company’s CEO.
• The company entered into an Executive Employment Agreement with Mr. Elmore dated February 6, 2026 (employment commencement March 16, 2026). The agreement is filed as Exhibit 10.1 with certain immaterial provisions omitted.

Key Details

• Base salary: $375,000 per year.
• Annual bonus: Target 35% of base salary; first-year bonus is guaranteed.
• Sign-on: $100,000 payable at start, repayable if Mr. Elmore voluntarily leaves within 12 months.
• Equity and vesting: Restricted stock units with grant-date value of $300,000 — 20% vests on grant; remaining vests in equal installments over the next 24 months. Eligible for additional equity tied to international business milestones.
• Severance: If terminated without cause or resigns for good reason, eligible for accrued pay plus cash severance equal to 2× (base salary + target bonus) and up to 24 months of health coverage (or cash in lieu), subject to a release; enhanced protections apply on certain change-in-control events.
• Background: Mr. Elmore has 20+ years in medical device/life sciences leadership, including senior roles at Invibio (Victrex plc) — Global Head of Sales (2010–2021) and Core Business Director since Sept. 2021.

Why It Matters

• This is a material executive appointment that clarifies SINTX’s operational leadership: Eric Olson remains CEO and Chairman while day-to-day company presidency moves to an experienced medical-device executive.
• Compensation and equity terms align Mr. Elmore’s incentives with commercial and international growth goals (including milestone-based awards) while providing the company customary severance protections.
• For investors, the change signals a focus on commercial execution and international expansion led by a hire with relevant industry experience; it does not represent a change in the CEO role.